Harvard Bioscience (HBIO) EV to CFO (2010 - 2026)

Harvard Bioscience (HBIO) has reported EV to CFO for 17 consecutive years, with 66.13 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to CFO rose 1399.38% year-over-year to 66.13 in Q2 2026; TTM through Jun 2026 was 33.02, a 1699.75% increase from a year earlier, with the FY2025 full-year figure at 3.17, down 94.86% from the prior year.
• EV to CFO was 66.13 for Q2 2026 at Harvard Bioscience, up from 22.46 in the prior quarter.
• Over five years, EV to CFO peaked at 156.39 in Q3 2022 and troughed at 763.9 in Q2 2022.
• A 5-year average of 38.32 and a median of 26.34 in 2023 frame the typical range for EV to CFO.
• Across the five-year window, EV to CFO sank 531.55% in 2025 and surged 1399.38% in 2026, its largest moves.
• Over 5 years, EV to CFO stood at 41.83 in 2022, then increased by 26.61% to 52.96 in 2023, then decreased by 2.7% to 51.53 in 2024, then sank by 531.55% to 222.38 in 2025, then soared by 129.74% to 66.13 in 2026.
• The last three EV to CFO figures came in at 66.13 (Q2 2026), 22.46 (Q1 2026), and 222.38 (Q4 2025), per Business Quant data.